Skip to main content
Clinical Trials/JPRN-jRCT1050220128
JPRN-jRCT1050220128
Active, not recruiting
未知

Patient prognosis evaluation with retrospective data in severe perinatal, benign perinatal or infantile HPP: A pooled analysis from the post-marketing study and perinatal findings surveillance - HPP-PERINATAL study

Sawai Hideaki0 sites40 target enrollmentDecember 8, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Sawai Hideaki
Enrollment
40
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 8, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Sawai Hideaki

Eligibility Criteria

Inclusion Criteria

  • 1\. At the time of the PMS data lock in July 2021, Strensiq Specified drug use\-results survey (post\-marketing survey) Patients should have have provided data to PMS prior the data base lock date above.
  • 2\. Patients diagnosed with perinatal severe hypophosphatasia, perinatal benign hypophosphatasia, or infantile hypophosphatasia
  • 3\. A patient whose legal representative or patient can give written consent to provide patient information and a patient whose mother can give written consent to provide maternal information.

Exclusion Criteria

  • 1\. Patients diagnosed with non\-perinatal and non\-infantile hypophosphatasia
  • 2\. Patients in whom fetal ultrasound image data including the number of weeks of gestation before and after 28 \~ 31 weeks of gestation cannot be obtained

Outcomes

Primary Outcomes

Not specified

Similar Trials